National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Everolimus added to National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines as subsequent therapy following failure of tyrosine kinase inhibitor therapy (TKI)

On Monday, April 13, 2009, everolimus was added to the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer as a category 1 option for relapsed or unresectable stage IV disease in patients with predominant clear cell histology who have progressed on prior TKI therapy.